Anuh Pharma Limited

ANUHPHR6

INE489G01022

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 06:00:51 2024-05-29 EDT			5-day change	1st Jan Change
230.9 ^INR	-0.47%		-1.70%	+57.50%

05-17	Anuh Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
05-17	Anuh Pharma Limited Recommends Dividend for the Financial Year Ended 31 March 2024	CI

Anuh Pharma Limited Announces Resignation of Lalitkumar P Shah as Non-Executive Director

February 10, 2023 at 06:43 am

Anuh Pharma Limited announced that Mr. Lalitkumar P Shah, Non-Executive Director of the company has vide his resignation letter dated February 10, 2023, resigned from the Board of the Company with immediate effect. Reason for change is due to ill health and age of 88 years.

Latest news about Anuh Pharma Limited

Anuh Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-17	CI
Anuh Pharma Limited Recommends Dividend for the Financial Year Ended 31 March 2024	05-17	CI
Anuh Pharma Limited Approves Final Dividend for the Financial Year Ended 2022-2023	04-08	CI
Anuh Pharma Limited Appoints Manan Jayesh Vadhan as Company Secretary and Compliance Officer	04-04	CI
Anuh Pharma Limited Announces Completion of Tenure of Jasvantlal Girdharlal Shah as Independent Director	04-01	CI
Anuh Pharma Gets European Regulator's Nod for Anti-Malarial Drug	02-28	MT
Anuh Pharma Limited Announces Resignation of Jinal Dharmil Mehtalia as Company Secretary and Compliance Officer, Effective 14 February, 2024	02-12	CI
Anuh Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-09	CI
Anuh Pharma Limited Announces the Resignation of Hemant Aunt as Company Secretary and Compliance Officer	01-11	CI
Anuh Pharma Limited Announces Appointment of Ms. Jinal Ajay Shah as Company Secretary and Compliance Officer, Effective from 15 January 2024	01-05	CI
Anuh Pharma Limited Approves the Board Appointments	12-13	CI
Anuh Pharma Limited Approves Board Appointments	11-10	CI
Anuh Pharma Limited Approves Board Appointments	23-08-19	CI
Anuh Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-11	CI
Anuh Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-19	CI
Anuh Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-19	CI
Anuh Pharma Limited Announces Board Changes	23-05-19	CI
Anuh Pharma Limited Recommends Final Dividend for the Financial Year Ended 31 March 2023	23-05-19	CI
Anuh Pharma Limited Announces Resignation of Lalitkumar P Shah as Non-Executive Director	23-02-10	CI
Anuh Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-10	CI
Anuh Pharma Limited Approves Appointment of Hemant Auti as the Company Secretary & Compliance Officer	23-01-06	CI
Anuh Pharma Limited Announces Resignation of Bharat Gangani as Company Secretary and Compliance Officer	22-10-20	CI
Anuh Pharma Limited Approves Final Dividend for the Financial Year Ended 2021-2022	22-08-06	CI
Anuh Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-05	CI
Anuh Pharma Limited Recommends Final Dividend for the Financial Year Ended 31 March 2022	22-05-14	CI

Chart Anuh Pharma Limited

Duration

Period

More charts

Company Profile

Anuh Pharma Limited is an India-based bulk drug manufacturing company. The Company is engaged in the business of manufacturing active pharmaceutical ingredients (API). The Company manufactures Macrolides, Anti-TB, Anti-Bacterials, Anti-Malarial, Anti-Hypertension, Expectorant and Corticosteroids products. Its Macrolides products include Erythromycin, Erythromycin Ethyl Succinate, Erythromycin Stearate, Erythromycin Estolate, Erythromycin Propionate, Erythromycin Phosphate, Erythromycin 11,12 Carbonate and Azithromycin. Its Anti-TB products include Pyrazinamide and Isoniazid. Its Anti-Malarial products include Sulfadoxine and Pyrimethamine. Anti-Bacterials products include Chloramphenicol and Chloramphenicol Palmitate. Anti-Hypertension products include Losartan Potassium, Telmisartan and Atorvastatin Calcium. Its Expectorant product includes Ambroxol Hydrochloride. Its Quinolones product includes Moxifloxacin Hydrochloride.

Sector

Pharmaceuticals

Calendar

2024-08-08 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ANUH PHARMA LIMITED	+57.50%	140M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+17.05%	42.25B
OTSUKA HOLDINGS CO., LTD.	+15.37%	21.27B
SANDOZ GROUP AG	+19.44%	15.23B
CIPLA LIMITED	+19.95%	14.36B
ZYDUS LIFESCIENCES LIMITED	+51.89%	12.74B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-12.40%	6.61B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.28%	5.66B